Korean-Japanese Billionaire Masayoshi Son’s 2022 Portfolio: 5 Stocks to Watch

3. AbCellera Biologics Inc. (NASDAQ:ABCL)

SB Management’s Stake Value: $75.70 million

Percentage of SB Management’s 13F Portfolio: 14.67%

Number of Hedge Fund Holders: 18

AbCellera Biologics Inc. (NASDAQ:ABCL) operates an AI-powered platform which analyzes the database of natural immune systems to discover antibodies that can be used to develop drugs. In February, Covid antibody treatment Bebtelovimab, discovered by AbCellera Biologics Inc. (NASDAQ:ABCL), was given the FDA Emergency Use Authorization for treatment of mild-to-moderate Covid. This drug was developed in collaboration with Eli Lilly And Co (NYSE:LLY), and is effective against the Omicron variant.

Piper Sandler analyst Do Kim on May 11 kept an ‘Overweight’ rating on AbCellera Biologics Inc. (NASDAQ:ABCL) shares, and lowered the price target to $21 from $28. The firm beat Q1 expectations due to higher royalty revenue from sales of its Covid antibody treatment, according to the analyst, who lowered the price target on account of higher interest rates and a higher beta.

In the first quarter, AbCellera Biologics Inc. (NASDAQ:ABCL) posted EPS of $0.54, outperforming analysts’ forecasts by $0.12. Quarterly revenue of $316.6 million was also recorded above market estimates by $96.8 million.

At the close of the fourth quarter, 18 hedge funds reported bullish bets on AbCellera Biologics Inc. (NASDAQ:ABCL), as compared to 21 hedge funds a quarter ago. In Q1 2022, Baker Bros. Advisors was the largest shareholder of the firm, with 10.45 million shares worth $101.9 million.